Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-10 | Dr. Spiegel has served as a director of the Company since September, 2018. Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals, including large pharmaceutical and biotechnology companies, and academic startups as well as an advisor to venture capital and private equity funds. Dr. Spiegel was an Assistant Professor and Director of the Developmental Therapeutics Program at New York University Medical Center and then spent 25 years at Schering-Plough (subsequently acquired by Merck & Co.), where he joined as the first Director for Oncology Clinical Research. He subsequently held a series of senior executive positions, including Senior Vice President for Worldwide Clinical Research and Chief Medical Officer. During his time at Schering-Plough he led teams that took numerous drug candidates through clinical development and was involved with over 30 New Drug Application approvals by the U.S. FDA. For the last seven years, he has been a consultant to the biotech industry and has served on the Scientific Advisory Board and Board of Directors of multiple biotech companies. Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. |
| 2019-09-27 | Dr. Robert Spiegel(11) - Includes options to purchase 8,576 shares of common stock that are exercisable within 60 days of September 13, 2019. |
| 2020-05-12 | Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. We believe Dr. Spiegel’s qualifications to serve on the Board of Directors include his extensive knowledge and business experience in the biotechnology industry. |
| 2021-04-29 | Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals, including large pharmaceutical and biotechnology companies, and academic startups as well as an advisor to venture capital and private equity funds. He received his B.A. from Yale University and his M.D. from the University of Pennsylvania. |
| 2022-04-26 | Dr. Spiegel received his B.A. from Yale University and his M.D. from the University of Pennsylvania. |
| 2023-11-14 | Dr. Robert Spiegel Represents beneficial ownership of less than 1% of the outstanding shares of our common stock. |
| 2024-05-08 | Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals, including large pharmaceutical and biotechnology companies, and academic startups as well as an advisor to venture capital and private equity funds. He received his B.A. from Yale University and his M.D. from the University of Pennsylvania. |
Data sourced from SEC filings. Last updated: 2026-02-03